PMID- 29308737
OWN - NLM
STAT- MEDLINE
DCOM- 20190925
LR  - 20190925
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 24
IP  - 4
DP  - 2018
TI  - Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute 
      Coronary Syndromes after Percutaneous Coronary Interventions Compared to 
      Clopidogrel? Insights from Randomized Clinical Trials, Registries and 
      Meta-analysis.
PG  - 465-477
LID - 10.2174/1381612824666180108121834 [doi]
AB  - BACKGROUND: According to ACC/ AHA guidelines, a minimum of 1 year of dual anti- 
      platelet therapy (DAPT) consisting of aspirin and a platelet ADP-receptor 
      antagonist (P2Y12 inhibitor) is recommended for patients presenting acute 
      coronary syndromes (ACS), regardless of which type of revascularization is 
      performed during the acute event. METHODS: The purpose of this presentation was 
      to review the present data either from a direct randomized comparison among the 
      three compounds and also large prospective observational registries and 
      meta-analysis were analyzed in detail. With this aim, we performed an extensive 
      large search from PubMed/Medline Journals identifying studies comparing fashion 
      the new P2Y12 inhibitors in patients with ACS including ST elevation myocardial 
      infarction (STEMI) in direct and indirect manner. RESULTS: Pivotal large 
      randomized clinical trials (RCT) in patients with ACS including STEMI, comparing 
      clopidogrel, a first generation P2Y12 inhibitor against the newer prasugrel and 
      ticagrelor showed major efficacy advantages of the latters although both drugs 
      had more bleeding risk than clopidogrel. Direct comparisons of prasugrel and 
      ticagrelor from large RCT are not yet available, however, several observational 
      registries and metaanalysis reported results from an indirect comparison between 
      both compounds. Major findings and limitations of each of these studies were 
      identified, highlighted and discussed. CONCLUSION: Prasugrel and ticagrelor are 
      both more effective than clopidogrel to prevent adverse cardiac events in 
      patients with ACS. Compared to ticagrelor, prasugrel appears to be more effective 
      in patients with STEMI, although lack of randomized data didn't allow to draw 
      definitive conclusions.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Rodriguez, Alfredo E
AU  - Rodriguez AE
AD  - Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine, Cardiovascular 
      Research Center (CECI), Buenos Aires, Argentina.
FAU - Rodriguez-Granillo, Alfredo M
AU  - Rodriguez-Granillo AM
AD  - Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine, Cardiovascular 
      Research Center (CECI), Buenos Aires, Argentina.
FAU - Ascarrunz, Sergio D
AU  - Ascarrunz SD
AD  - Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine, Cardiovascular 
      Research Center (CECI), Buenos Aires, Argentina.
FAU - Peralta-Bazan, Francisco
AU  - Peralta-Bazan F
AD  - Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine, Cardiovascular 
      Research Center (CECI), Buenos Aires, Argentina.
FAU - Cho, Mi Y
AU  - Cho MY
AD  - Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine, Cardiovascular 
      Research Center (CECI), Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
SB  - IM
MH  - *Acute Coronary Syndrome/drug therapy/surgery
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Humans
MH  - Observational Studies as Topic
MH  - *Percutaneous Coronary Intervention
MH  - Prasugrel Hydrochloride/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Registries
MH  - Ticagrelor/*therapeutic use
OTO - NOTNLM
OT  - Prasugrel
OT  - aspirin
OT  - clopidogrel
OT  - dual antiplatelet therapy
OT  - stent thrombosis
OT  - ticagrelol.
EDAT- 2018/01/09 06:00
MHDA- 2019/09/26 06:00
CRDT- 2018/01/09 06:00
PHST- 2017/11/24 00:00 [received]
PHST- 2017/12/26 00:00 [revised]
PHST- 2018/01/01 00:00 [accepted]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - CPD-EPUB-87763 [pii]
AID - 10.2174/1381612824666180108121834 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834.